Ozgur Oksuz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ozgur Oksuz has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Danny Reinberg
Howard Hughes Medical Institute, University of Miami, Miami, FL 33136, USA
5 shared publications - Chul-Hwan Lee
Seoul National University
4 shared publications - Jia-Ray Yu
Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, USA
3 shared publications - Bradley E. Bernstein
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
2 shared publications Esther Rheinbay
Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
2 shared publicationsMario L. Suvà
Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
2 shared publications
Latest Publications
- Top Cited Papers
- 19 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 368 (6497) , 1386-1392
Partitioning of cancer therapeutics in nuclear condensates
Drug partitioning in nuclear condensates: There is increasing interest in the function of phase-separated biomolecular condensates in cells because of their distinct properties and expanding roles in important biological processes. Klein et al. considered the fate of small-molecule therapeutics in the context of nuclear condensates (see the Perspective by Viny and Levine). They show that certain antineoplastic drugs have physicochemical properties that cause them to concentrate preferentially in condensates, both in vitro and in cancer cells. This property influences drug activity, and protein mutations that alter condensate formation can lead to drug resistance. Optimizing condensate partitioning may be valuable in developing improved therapeutics. Science , this issue p. 1386 ; see also p. 1314
- 19 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 368 (6497) , 1386-1392
Top Cited PapersPartitioning of cancer therapeutics in nuclear condensates
Drug partitioning in nuclear condensates: There is increasing interest in the function of phase-separated biomolecular condensates in cells because of their distinct properties and expanding roles in important biological processes. Klein et al. considered the fate of small-molecule therapeutics in the context of nuclear condensates (see the Perspective by Viny and Levine). They show that certain antineoplastic drugs have physicochemical properties that cause them to concentrate preferentially in condensates, both in vitro and in cancer cells. This property influences drug activity, and protein mutations that alter condensate formation can lead to drug resistance. Optimizing condensate partitioning may be valuable in developing improved therapeutics. Science , this issue p. 1386 ; see also p. 1314
- Open Access
- 11 October 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (10) , eaay3068
LEDGF and HDGF2 relieve the nucleosome-induced barrier to transcription in differentiated cells
Chromatin-bound LEDGF and HDGF2 proteins allow RNAPII to overcome the nucleosome-induced block to transcription.
- 11 October 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (10) , eaay3068
Open AccessLEDGF and HDGF2 relieve the nucleosome-induced barrier to transcription in differentiated cells
Chromatin-bound LEDGF and HDGF2 proteins allow RNAPII to overcome the nucleosome-induced block to transcription.
- Open Access
- 23 May 2019
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 33 (15-16) , 903-935
PRC2 is high maintenance
As the process that silences gene expression ensues during development, the stage is set for the activity of Polycomb-repressive complex 2 (PRC2) to maintain these repressed gene profiles. PRC2 catalyzes a specific histone posttranslational modification (hPTM) that fosters chromatin compaction. PRC2 also facilitates the inheritance of this hPTM through its self-contained “write and read” activities, key to preserving cellular identity during cell division. As these changes in gene expression occur without changes in DNA sequence and are inherited, the process is epigenetic in scope. Mutants of mammalian PRC2 or of its histone substrate contribute to the cancer process and other diseases, and research into these aberrant pathways is yielding viable candidates for therapeutic targeting. The effectiveness of PRC2 hinges on its being recruited to the proper chromatin sites; however, resolving the determinants to this process in the mammalian case was not straightforward and thus piqued the interest of many in the field. Here, we chronicle the latest advances toward exposing mammalian PRC2 and its high maintenance.
- 23 May 2019
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 33 (15-16) , 903-935
Open AccessPRC2 is high maintenance
As the process that silences gene expression ensues during development, the stage is set for the activity of Polycomb-repressive complex 2 (PRC2) to maintain these repressed gene profiles. PRC2 catalyzes a specific histone posttranslational modification (hPTM) that fosters chromatin compaction. PRC2 also facilitates the inheritance of this hPTM through its self-contained “write and read” activities, key to preserving cellular identity during cell division. As these changes in gene expression occur without changes in DNA sequence and are inherited, the process is epigenetic in scope. Mutants of mammalian PRC2 or of its histone substrate contribute to the cancer process and other diseases, and research into these aberrant pathways is yielding viable candidates for therapeutic targeting. The effectiveness of PRC2 hinges on its being recruited to the proper chromatin sites; however, resolving the determinants to this process in the mammalian case was not straightforward and thus piqued the interest of many in the field. Here, we chronicle the latest advances toward exposing mammalian PRC2 and its high maintenance.
- Open Access
- 5 October 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 4 (10) , eaau5935
Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma
H3K27M transiently recruits PRC2 to chromatin but persistently affects its activity, leading to an aberrant epigenome in DIPG.
- 5 October 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 4 (10) , eaau5935
Open AccessMultiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma
H3K27M transiently recruits PRC2 to chromatin but persistently affects its activity, leading to an aberrant epigenome in DIPG.
- 1 June 2018
- Published by Elsevier in Molecular Cell
- Vol. 70 (6) , 1149-1162.e5
Capturing the Onset of PRC2-Mediated Repressive Domain Formation
- 1 June 2018
- Published by Elsevier in Molecular Cell
- Vol. 70 (6) , 1149-1162.e5
Capturing the Onset of PRC2-Mediated Repressive Domain Formation
- 7 December 2016
- Published by Springer Nature
- Vol. 1487, 289-301
Probing Chromatin Modifications in Response to ERK Signaling
Chromatin immunoprecipitation (ChIP) is a technique used to determine the association of proteins or histone modifications with chromatin regions in living cells or tissues, and is used extensively in the chromatin biology field to study transcriptional and epigenetic mechanisms. Increasing evidence points to an epigenetic coordination of signaling cascades, such as ERK, that regulate key processes in development and disease, revealing novel principles of gene regulation. Here we describe a detailed protocol for performing chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) for probing histone modifications regulated by ERK signaling in mouse ESCs.
- 7 December 2016
- Published by Springer Nature
- Vol. 1487, 289-301
Probing Chromatin Modifications in Response to ERK Signaling
Chromatin immunoprecipitation (ChIP) is a technique used to determine the association of proteins or histone modifications with chromatin regions in living cells or tissues, and is used extensively in the chromatin biology field to study transcriptional and epigenetic mechanisms. Increasing evidence points to an epigenetic coordination of signaling cascades, such as ERK, that regulate key processes in development and disease, revealing novel principles of gene regulation. Here we describe a detailed protocol for performing chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) for probing histone modifications regulated by ERK signaling in mouse ESCs.
- Top Cited Papers
- 1 November 2014
- Published by Elsevier in Cancer Cell
- Vol. 26 (5) , 668-681
EWS-FLI1 Utilizes Divergent Chromatin Remodeling Mechanisms to Directly Activate or Repress Enhancer Elements in Ewing Sarcoma
- 1 November 2014
- Published by Elsevier in Cancer Cell
- Vol. 26 (5) , 668-681
Top Cited PapersEWS-FLI1 Utilizes Divergent Chromatin Remodeling Mechanisms to Directly Activate or Repress Enhancer Elements in Ewing Sarcoma
- Open Access
- 1 May 2013
- Published by Elsevier in Cell Reports
- Vol. 3 (5) , 1567-1579
An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma
- 1 May 2013
- Published by Elsevier in Cell Reports
- Vol. 3 (5) , 1567-1579
Open AccessAn Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma